



## Commercial/Healthcare Exchange PA Criteria *Effective: February 2017*

**Prior Authorization:** Eucrisa

**Products Affected:** Eucrisa 2% topical ointment

**Covered Uses:** Eucrisa is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months and older.

**Exclusion Criteria:** N/A

**Required Medical Information:**

1. Diagnosis
2. Previous medications tried/failed

**Age Restrictions:** 3 months of age and older

**Prescriber Restrictions:** N/A

**Coverage Duration:** 12 months

**Other Criteria:**

- A. Patient has a documented intolerance to, or treatment failure of, adequate trials of at least THREE (3) generic topical products FDA approved to treat atopic dermatitis including:
  - a. Tacrolimus
  - b. Low to Medium potency topical corticosteroids
  - c. Medium to High potency topical corticosteroids.

Note: Patients between the ages of 3 months and 2 years are not required to step through tacrolimus.

**References:**

1. Eucrisa full prescribing information. Pfizer Labs Inc., New York, NY.



Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	2/2017
2	Revision	Criteria update	All	7/2018
3	Update	Updated coverage duration to 12 months	Coverage Duration	2/4/2020
4	Update	Updated age restriction from 2 years to 3 months	Covered Uses Age Restriction Other Criteria	6/11/2020